The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Long-Term Safety and Effectiveness of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
Abstract
Objective: To evaluate the long-term safety and effectiveness of lisdexamfetamine dimesylate (LDX) in the treatment of adults with attention-deficit/hyperactivity disorder (ADHD). Methods: Following a 4-week, placebo-controlled, double-blind trial, 349 adults with ADHD were enrolled into an open-label, single-arm study for up to 12 months. Treatment was initiated at 30 mg/day and titrated up to 70 mg/day at subsequent visits to achieve optimal effectiveness and tolerability. Safety assessments included adverse events inquiries, vital signs, and electrocardiograms while the primary effectiveness assessment was the ADHD Rating Scale (ADHD-RS) total score. Results: A total of 191 (54.7%) subjects completed the study. The most common treatment-emergent adverse events (TEAEs) were upper respiratory tract infection (21.8%), insomnia (19.5%), headache (17.2%), dry mouth (16.6%), decreased appetite (14.3%), and irritability (11.2%). Most TEAEs were mild to moderate in severity. At endpoint, small but statistically significant increases in pulse and blood pressure were noted. Significant improvements in mean ADHD-RS total scores were observed at week 1 and sustained throughout the study ( P <.0001 at all postbaseline visits). At endpoint, the mean improvement from baseline ADHD-RS total score was 24.8 ( P <.0001). Conclusions: LDX demonstrated a safety profile consistent with long-acting stimulant use and provided continued effectiveness in adults with ADHD for up to 12 months.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The safety profile was similar to that observed in studies of LDX in adults with ADHD (Weisler et al, 2009;Wigal et al, 2010) and MDD (Trivedi et al, 2013) and was consistent with those of other long-acting stimulants (Medori et al, 2008;Reimherr et al, 2007).”
From Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder (2014) · cites this paper as Weisler et al, 2009
In the citing paper
“Additional crossover, open-label trial,25 as well as placebo-controlled studies comparing LDX with mixed amphetamine salts immediate-release (MAS-IR) tablets have also demonstrated the benefits of the stimulant compared with placebo”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [27]
In the citing paper
“LDX compared with MAS-IR demonstrated a trend in superiority in all the BRIEF major components: the overall measure of EF (GEC), behavior regulation (Behavioral Regulation Index [BRI]), and meta-cognition (Metacognition Index [MCI]) (trend at P < .06).”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [27]
In the citing paper
“The CGI-Severity of Illness (CGI-S) scores were significantly reduced for the LDX group compared with the MAS-IR group (P < .02).”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [27]
In the citing paper
“Both treatments resulted in significant improvements in the primary outcome measure of ADHD-RS scores and did not differ significantly from each other: LDX at 48.7% and MAS-IR at 45.1%.”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [27]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886 · cited 2×
“The death of 1 subject as a result of cocaine and alcohol toxicity was determined to be unrelated to LDX treatment, but stresses the importance of initial and ongoing assessment to minimize the potential impact of substance abuse in subjects with ADHD, two conditions that demonstrate high rates of comorbidity.(6) Cons…”
BackgroundResultSelf-citationBARKLEY, R. A., FISCHER, M., EDELBROCK, C. S., & SMALLISH, L. (1990) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199007000-00007 · Cited by 1,507
Biederman, J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.816 · Cited by 1,498
Barkley, R. A., Fischer, M., Smallish, L., & Fletcher, K. (2002) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.111.2.279 · Cited by 1,199
Greenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
Biederman, J., Faraone, S. V., Spencer, T. J., Mick, E., Monuteaux, M. C., & Aleardi, M. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0403 · Cited by 565
Biederman, J., Krishnan, S., Zhang, Y., McGough, J. J., & Findling, R. L. (2007) · Clinical Therapeutics · doi:10.1016/s0149-2918(07)80083-x · Cited by 404
Cited by
Amphetamine, past and present – a pharmacological and clinical perspective
Heal, D. J., Smith, S. L., Gosden, J., & Nutt, D. J. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113482532 · Cited by 617
“…for d-amphetamine (James et al., 2001; Pelham et al., 1990; Winsberg et al., 1974) MESamphetamine (Goodman et al., 2005; James et al., 2001; Pelham et al., 1999; Wigal et al., 2005) and lisdexamfetamine (Adler et al., 2008; Biederman et al., 2007a,b; Findling et al., 2008; Weisler et al., 2009).”
BackgroundMcElroy, S. L., Hudson, J. I., Mitchell, J. E., Wilfley, D., Ferreira-Cornwell, M. C., Gao, J., Wang, J., Whitaker, T., Jonas, J., & Gasior, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2162 · Cited by 322
Self-citationBolea-Alamañac, B., Nutt, D. J., Adamou, M., Asherson, P., Bazire, S., Coghill, D., Heal, D., Müller, U., Nash, J., Santosh, P., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113519509 · Cited by 287
“, 2008), and also in open-label, long-term investigations (Findling et al., 2008; Weisler et al., 2009).”
BackgroundLevin, F. R., Mariani, J. J., Specker, S., Mooney, M., Mahony, A., Brooks, D. J., Babb, D., Bai, Y., Eberly, L. E., Nunes, E. V., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.41 · Cited by 179
Methylphenidate and Risk of Serious Cardiovascular Events in Adults
Schelleman, H., Bilker, W. B., Kimmel, S. E., Daniel, G. W., Newcomb, C. W., Guevara, J. P., Cziraky, M. J., Strom, B. L., & Hennessy, S. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010125 · Cited by 124
Metadata
- Authors
- Weisler, R., Young, J., Mattingly, G., Gao, J., Squires, L., Adler, L., & 304 Study Group
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Venue
- CNS Spectrums
- Publisher
- Cambridge University Press (CUP)
- Published
- 2009-10
- Volume
- 14
- Issue
- 10
- Pages
- 573-586
- ISSN
- 1092-8529 (ISSN-L)
- 2165-6509
- OpenAlex
- W1853960255
- Cited by
- 94
- References
- 36
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 5 · 2017: 12 · 2016: 4 · 2015: 7 · 2014: 13 · 2013: 9 · 2012: 6
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Spectrums (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Social Sciences › Arts and Humanities › Philosophy › Neuroethics, Human Enhancement, Biomedical Innovations
- Keywords
- lisdexamfetamine dimesylate, adult ADHD, long-term safety, long-term effectiveness, stimulant medication, treatment-emergent adverse events, ADHD Rating Scale, dose titration
- MeSH terms
- Lisdexamfetamine Dimesylate, Adolescent, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Dextroamphetamine, Dose-Response Relationship, Drug, Electrocardiography, Female, Humans, Longitudinal Studies, Male, Middle Aged, Psychiatric Status Rating Scales, Severity of Illness Index, Time Factors, Young Adult, Vital Signs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Safety and Effectiveness of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder. https://app.cochat.ai/papers/10.1017/s1092852900024056
- The paper
- Weisler, R., Young, J., Mattingly, G., Gao, J., Squires, L., Adler, L., & 304 Study Group. (2009). Long-Term Safety and Effectiveness of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder. CNS Spectrums. https://doi.org/10.1017/s1092852900024056
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.